| 证券代码 | LOXO.O |
| 证券名称 | Loxo Oncology Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-08-01 |
| 首发价格(元) | 13 USD |
| 首发数量(股) | 5261538 |
| 首发募资额(元) | 68,399,994.00 USD |
| 首发主承销商 | Cowen and Company, LLC,Stifel Nicolaus & Company, Incorporated |
| 货币单位 | USD |
| 公司名称 | Loxo Oncology, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 281 Tresser Blvd., 9th Floor, Stamford, Connecticut, USA |
| 成立日期 | 2013-05-09 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.loxooncology.com |
| 电话 | +1 (203) 653-3880 |
| 传真 | - |
| 公司简介 | Loxo Oncology, Inc. is a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers. Their pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. They believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, with the intention of delivering best-in-class disease control and safety. Their management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. |